Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Neurological Sciences

• Publication date

  2019-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10072-019-03778-7PMID 30847674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis)

  2019cited by this paper
• 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).

  2019cited by this paper
• Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

  2018cited by this paper
• Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations

  2018cited by this paper
• Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

  2018cited by this paper
• An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy

  2018cited by this paper
• Development and validation of the Charcot-Marie-Tooth Disease Infant Scale

  2018cited by this paper
• Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1)

  2018cited by this paper
• Neuropathy.

  2018cited by this paper
• The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage

  2018cited by this paper
• Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation—a prospective single‐center cohort study

  2018cited by this paper
• Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm

  2018cited by this paper
• Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.

  2018cited by this paper
• Estimating the global prevalence of transthyretin familial amyloid polyneuropathy

  2018cited by this paper
• Transthyretin familial amyloid polyneuropathy: an update

  2018cited by this paper
• Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development

  2018cited by this paper
• Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

  2018cited by this paper
• Update review of the acute porphyrias

  2017cited by this paper
• Liver transplant reverses biochemical imbalance in mitochondrial neurogastrointestinal encephalomyopathy.

  2017cited by this paper
• Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study

  2017cited by this paper
• Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy

  2017cited by this paper
• Long-Term Sustained Effect of Liver-Targeted Adeno-Associated Virus Gene Therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy

  2017cited by this paper
• PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models

  2017cited by this paper
• New developments in Charcot–Marie–Tooth neuropathy and related diseases

  2017cited by this paper
• First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

  2016cited by this paper
• Sport activity in Charcot–Marie–Tooth disease: A case study of a Paralympic swimmer

  2016cited by this paper
• Novel outcome measures for Charcot−Marie−Tooth disease: validation and reliability of the 6‐min walk test and StepWatch™ Activity Monitor and identification of the walking features related to higher quality of life

  2016cited by this paper
• Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease

  2016cited by this paper
• Rehabilitation Management of the Charcot–Marie–Tooth Syndrome

  2016cited by this paper
• “Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy

  2016cited by this paper
• Liver

  2016cited by this paper
• Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

  2016cited by this paper
• Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

  2016cited by this paper
• Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

  2016cited by this paper
• Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

  2016cited by this paper
• Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides

  2016cited by this paper
• Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy.

  2016cited by this paper
• Charcot-Marie-Tooth (CMT) Hereditary Neuropathy Overview

  2016cited by this paper
• Quantitative Comparison Between Amyloid Deposition Detected by (99m)Tc-Diphosphonate Imaging and Myocardial Deformation Evaluated by Strain Echocardiography in Transthyretin-Related Cardiac Amyloidosis.

  2016cited by this paper
• Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area

  2015cited by this paper
• Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

  2015cited by this paper
• Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?

  2015cited by this paper
• Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification

  2015cited by this paper
• Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.

  2015cited by this paper
• Systematic review of exercise for Charcot‐Marie‐Tooth disease

  2015cited by this paper
• Rapid progression of familial amyloidotic polyneuropathy

  2015cited by this paper
• A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK

  2015cited by this paper
• Role of delta-aminolevulinic acid in the symptoms of acute porphyria.

  2015influential reference
• RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice

  2014cited by this paper
• Porphyria and its neurologic manifestations.

  2014cited by this paper
• An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

  2014cited by this paper
• The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease.

  2014cited by this paper
• Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy

  2014cited by this paper
• Is overwork weakness relevant in Charcot–Marie–Tooth disease?

  2014cited by this paper
• Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis

  2014cited by this paper
• Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy

  2013cited by this paper
• Reversible folding of human peripheral myelin protein 22, a tetraspan membrane protein.

  2013cited by this paper
• Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria

  2013cited by this paper
• Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis

  2013cited by this paper
• Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

  2013cited by this paper
• Guideline of transthyretin-related hereditary amyloidosis for clinicians

  2013cited by this paper
• GABA-B receptors in the PNS have a role in Schwann cells differentiation?

  2013cited by this paper
• Tafamidis for transthyretin familial amyloid polyneuropathy

  2012cited by this paper
• Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU

  2012cited by this paper
• Familial amyloid polyneuropathy.

  2011cited by this paper
• Role of naturally occurring osmolytes in protein folding and stability.

  2009cited by this paper
• Familial amyloid polyneuropathy: a clinico-pathologic study.

  2009cited by this paper
• High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and Dependence

  2008cited by this paper
• Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease

  2007cited by this paper
• The molecular biology and clinical features of amyloid neuropathy

  2007cited by this paper
• Open-label study of hemin for acute porphyria: clinical practice implications.

  2006cited by this paper
• New therapies for muscular dystrophy: cautious optimism.

  2004cited by this paper
• Immunolocalization and activation of transcription factor nuclear factor kappa B in dysimmune neuropathies and familial amyloidotic polyneuropathy.

  2004cited by this paper
• Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration

  2003cited by this paper
• Dystrophin-associated glycoproteins: their possible roles in the pathogenesis of Duchenne muscular dystrophy.

  1993cited by this paper
• The Orphan Drug Act: The First 7 Years

  1991cited by this paper
• Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

  1987cited by this paper
• Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

  1987cited by this paper

• Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin‐mediated amyloidosis with polyneuropathy

  2024cites this paper
• Exploration of the Noncoding Genome for Human-Specific Therapeutic Targets—Recent Insights at Molecular and Cellular Level

  2023cites this paper
• Mechanisms and treatment strategies of demyelinating and dysmyelinating Charcot-Marie-Tooth disease

  2023cites this paper
• Gene Therapies for Spinal Muscular Atrophy and Duchenne Muscular Dystrophy: A Pathbreaking Moment in Therapeutics

  2022cites this paper
• Therapeutic tools for inherited neuropathies.

  2022cites this paper
• Roles of Krüppel-like factor 6 splice variant 1 in the development, diagnosis, and possible treatment strategies for non-small cell lung cancer.

  2022cites this paper
• Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area

  2021cites this paper
• Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS

  2021cites this paper
• Very Early Onset of ATTRE89Q Amyloidosis in a Homozygous Patient

  2021cites this paper
• Hereditary motor neuropathies and overlapping conditions

  2021cites this paper
• Acute Hepatic Porphyria: Pathophysiological Basis of Neuromuscular Manifestations

  2021cites this paper
• Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy

  2021cites this paper
• Mechanisms and Treatments in Demyelinating CMT

  2021cites this paper
• Rare among Rare: Phenotypes of Uncommon CMT Genotypes

  2021cites this paper
• Advances in Treatments in Muscular Dystrophies and Motor Neuron Disorders.

  2021cites this paper
• Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy

  2021cites this paper
• Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects

  2020cites this paper
• Mitochondrial disorders

  2020cites this paper
• Hereditary transthyretin amyloidosis overview

  2020cites this paper
• The frequency of central nervous system complications in the Cypriot cohort of ATTRV30M neuropathy transplanted patients

  2020cites this paper
• Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center

  2020cites this paper
• Rare Neurologic Diseases and Neurological Sciences: a report for the celebration of the 2020 Rare Diseases Day

  2020cites this paper
• 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

  2020cites this paper
• Non-coding RNAs in Cardiovascular Diseases

  2020cites this paper
• Small Interfering RNAs and RNA Therapeutics in Cardiovascular Diseases.

  2020cites this paper
• From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis

  2020cites this paper
• Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis

  2020cites this paper
• Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats

  2020cites this paper
• ATTRv amyloidosis Italian Registry: clinical and epidemiological data

  2020cites this paper
• A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

  2020cites this paper
• New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy.

  2020cites this paper
• Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy

  2020cites this paper
• Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases

  2020cites this paper
• Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy

  2020cites this paper
• Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation

  2019cites this paper
• Translational Medicine in Neurological Disorders: A Genomic Perspective

  2019cites this paper
• Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy

  2019cites this paper
• Development and validation of the Charcot-Marie-Tooth Disease Infant Scale

  2018cites this paper